MHRA pushes Yellow Card reporting as #MedSafetyWeek returns for 2026
The MHRA is using this year’s #MedSafetyWeek to sharpen a message that sits at the center of pharmacovigilance: suspected side effects should be reported, not dismissed. Running from 2 to 8 November 2026, the campaign places the Yellow Card scheme back in the foreground for clinicians, patients, and caregivers who encounter unexpected harm from medicines, vaccines, medical devices, and related products.
The campaign theme — “side effects: don’t ignore them, report them!” — is straightforward, but the clinical logic behind it is not trivial. A suspected adverse reaction can be the earliest signal of a problem that has not yet become visible in trials, routine practice, or product labeling. In real-world care, even a single report can matter when the event is unusual, severe, linked to a newly introduced product, or appears after a dose change, an interaction, or long-term exposure.
One report can be enough to start a safety review.
Why the Yellow Card scheme remains central to medicines safety
The Yellow Card scheme is the UK’s reporting system for suspected side effects and safety concerns involving medicines, vaccines, blood products, medical devices, e-cigarettes, vapes, and their refills. It also accepts reports related to defective or falsified products. The framework depends on the people closest to the patient experience: health professionals who recognize a pattern, patients who notice a change in how they feel, and caregivers who can spot adverse effects that might otherwise be missed.
Clinically, this matters because adverse reactions do not always announce themselves in a tidy way. Some appear soon after treatment starts or stops. Others emerge slowly, after a switch in formulation, route, dose, or device. Some are only recognized once laboratory abnormalities, imaging, or device performance issues accumulate enough evidence to connect the dots. A rash, arrhythmia, confusion, or unexplained deterioration may be attributed first to the underlying disease; reporting helps separate coincidence from causation and gives regulators a way to see whether a broader pattern is forming.
Healthcare professionals are reminded that only suspicion is required. A completed diagnosis is not necessary before a Yellow Card report is submitted. That lowers the threshold for action and aligns with the reality of bedside medicine, where certainty often arrives late.
New digital tools are aimed at reducing friction in reporting
This year’s update goes beyond campaign messaging. The Yellow Card website and app now include NHS Login integration, allowing users to create a new account or link an existing one. In practical terms, that removes one of the persistent barriers to reporting: the extra credential burden that often slows digital engagement.
The app has also shifted to a progressive web app format. That brings the interface closer to the website experience across devices, with real-time updates that no longer depend on users downloading a new app version. The change is especially relevant for a reporting tool, where delays in interface updates can become delays in safety surveillance.
The upgraded app now supports direct reporting of issues involving defective medicines and falsified products. Data publications can also be viewed within the app, widening access to information that may help clinicians interpret safety trends or explain why a particular report matters. The reduced download size is a practical benefit for routine use, particularly in settings where devices are shared, storage is limited, or users rely on mobile access during busy clinical shifts.
Security, access, and the practical burden of surveillance
Multi-factor authentication has been added to strengthen account security and protect reporter and patient information. In a safety-reporting system that may contain sensitive clinical details, that protection is not a cosmetic feature. It helps reduce the risk of unauthorized access while preserving the integrity of the reporting network.
The broader message is simple: if reporting is cumbersome, adverse events go unrecorded. If reporting is secure, accessible, and quick, the system captures more of the early warning signals that matter. That is true for medicines and equally true for devices, where software updates, artificial intelligence tools, and hardware malfunctions can all introduce new failure modes outside the scope of conventional drug monitoring.
What clinicians are being asked to do during the campaign
The MHRA is asking healthcare professionals to support awareness of the Yellow Card scheme through campaign materials, social media sharing, and e-learning resources. Posters, digital screens, waiting-room assets, and online content are part of the current outreach, but the clinical ask is more direct: recognize a suspected adverse effect, discuss it with the patient, and submit the report.
The campaign also emphasizes a simple reporting framework: know the medicine or device, check the right patient and product details, ask whether the patient understands what has happened, and report the suspected side effect or adverse incident. The process is designed to fit into routine care rather than sit outside it. When possible, reports should include medical history, concomitant medicines, onset timing, and treatment dates, because those details help the MHRA assess whether the event fits a plausible safety pattern.
Follow-up requests from the MHRA also matter. Safety surveillance is iterative, and the quality of the signal often depends on whether the original report can be expanded with missing clinical context.
Device incidents and falsified products remain part of the same safety picture
The campaign is not limited to pharmaceuticals. Reports can also be submitted for adverse incidents involving medical devices, including software, apps, and artificial intelligence, as well as concerns about defective or falsified products. Reporting pathways differ slightly across the UK nations: England and Wales use the Yellow Card website or app, Scotland routes incidents through the Incident Reporting & Investigation Centre and local systems, and Northern Ireland uses the Yellow Card route in line with local organizational policy.
That breadth reflects modern care. A safety problem may arise from the active ingredient, the delivery system, the algorithm, or the product itself. Pharmacovigilance now overlaps with digital health oversight, device surveillance, and counterfeit detection in a way that older reporting systems were never designed to handle on their own.
The message running through #MedSafetyWeek is a familiar one, but the stakes are unchanged: if a suspected side effect or device incident is seen and left unreported, the signal may never reach the regulator. If it is reported, the event becomes part of a national safety system built to detect harm early and prevent the next patient from encountering the same problem.